Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Original Article

T.K. Choueiri, P. Tomczak, S.H. Park, B. Venugopal, T. Ferguson, S.N. Symeonides, J. Hajek, Y.-H. Chang, J.-L. Lee, N. Sarwar, N.B. Haas, H. Gurney, P. Sawrycki, M. Mahave, M. Gross-Goupil, T. Zhang, J.M. Burke, G. Doshi, B. Melichar, E. Kopyltsov, A. Alva, S. Oudard, D. Topart, H. Hammers, H. Kitamura, D.F. McDermott, A. Silva, E. Winquist, J. Cornell, A. Elfiky, J.E. Burgents, R.F. Perini, and T. Powles

N Engl J Med 2024;390:1359-1371

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
04/17/2024
Course expires: 
04/18/2026

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.